Asthma, COPD, Lung Cancer News | Treatment & Research Articles
WEBFuture of CRISPR: Gene Editing Technologies Herald Landmark Clinical Trials. By Jennifer Leavitt, MS. Following the approval of Casgevy for the treatment of sickle cell disease, a crusade of clinical trials are centering the therapeutic potential of CRISPR technologies.
GINA 2024 Asthma Update: Revised Recommendations on …
WEBJun 28, 2024 · The GINA 2024 asthma update includes new guidance on medications, monitoring, treatment goals, remission, cough variant asthma, children, and more.
2024 GOLD Report Reflects New Research on COPD Management
WEBDec 8, 2023 · Shifts in Thinking About COPD. Although many changes in the 2024 report reflect new research released from January 2022 to July 2023 (148 new references in total), the updated report does more than just incorporate this new research, said Dr Vogelmeier. The new “consolidated” report continues to refine the definition of COPD and pre-COPD ...
FDA Alert: Pulmonology Device, Drug Approvals and Recalls
WEB1 day ago · In the US, those with questions about this recall should contact their local service representative or Breas Medical Inc. service at 855-436-8724 ext. 110 or e-mail vivotechnicalsupport@breas.com. 19. FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device …
Updated 2023 GOLD Report Revises COPD Definitions and …
WEBJan 20, 2023 · The 2023 report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) — “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease” (COPD) 1 — details “an expanded range of therapies for COPD that now can be considered to improve mortality,” according to Gerard J. Criner, MD, FACP, FACCP, an author of the 2023 GOLD ...
Dupilumab for Severe Asthma Reduces Exacerbations, SCS …
WEB1 day ago · Dupilumab significantly reduced severe asthma exacerbations and systemic corticosteroid (SCS) prescriptions compared with omalizumab in patients with asthma using add-on maintenance treatment, researchers reported in the Journal of Allergy and Clinical Immunology.. The US-ADVANTAGE study compared the real-world effectiveness of dupilumab and omalizumab in patients aged 12 years or older with ...
Alternative Criteria Show Greater Sensitivity for Lung Cancer …
WEB1 day ago · These new criteria for lung cancer screening identified people with any smoking history for at least 40 years or people aged 60 to 80 years with a smoking history of 40 pack-years. Compared with USPSTF, these criteria selected similar numbers for screening but improved both sensitivity (91% vs 78%, P <.001) and specificity (86% vs 84%, P …
2022 Clinical Guidelines for Pulmonary ... - Pulmonology Advisor
WEBOctober 21, 2022. New clinical guidelines for the diagnosis and treatment of patients with pulmonary hypertension (PH) include an algorithm for earlier detection in the community and a recommendation for expedited referral for high-risk or complex patients. The guidelines were published simultaneously in the European Respiratory Journal and the ...
N-Acetylcysteine Nebulizer for COPD is Effective, Safe for Phlegm ...
WEB5 days ago · September 16, 2024. After 12 weeks of nebulized NAC, patients’ mean phlegm scores, as measured by the COPD assessment test, significantly decreased from 3.47 at baseline to 2.62. N-acetylcysteine (NAC) nebulizer therapy is effective and safe as a short-term (12-week) treatment for reducing phlegm in …
Nebulized Anticholinergic Therapy for Maintenance Treatment of …
WEBRevefenacin. Tiotropium. Umeclidinium. For select patients with COPD, nebulized drugs might offer an alternative to a breath-actuated, hand-held inhaler. 5 Adherence to inhaled medication in patients with COPD is low, with the nonadherence rate ranging from 50% to 80%. 6 Among the causes of nonadherence is the inability to use an inhaler as ...